Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-996 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-996 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 996 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Carmot Therapeutics; Roche

Most Recent Events

  • 17 Jul 2024 Results presented in the Roche Media Release.
  • 17 Jul 2024 According to a Genentech Media Release, Part 1 a single ascending dose in 40 participants with overweight or obesity (completed); part 2 a multiple ascending dose in three sequential cohorts 25 participants with obesity without type 2 diabetes (completed); part 3 a multiple ascending dose study in two sequential cohorts of 30 participants with obesity and type 2 diabetes (planned to be initiated in Q4 2024).
  • 17 Jul 2024 According to a Genentech Media Release, full study data will be presented at an upcoming medical meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top